Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial.
Baili ChenXiang GaoJie ZhongJianlin RenXuan ZhuZhan Ju LiuKaichun WuJasmina KalabicZhuqing YuBidan HuangNisha KwatraThao DoanAnne M RobinsonMin-Hu ChenPublished in: Therapeutic advances in gastroenterology (2020)
NCT02499783.